Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 872

1.

Ultrasound for HCC Surveillance: Still Looking for the Fortune Teller.

Foerster F, Galle PR.

Liver Transpl. 2018 Jul 18. doi: 10.1002/lt.25309. [Epub ahead of print]

PMID:
30021053
2.

Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients.

Labenz C, Baron JS, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

Aliment Pharmacol Ther. 2018 Aug;48(3):313-321. doi: 10.1111/apt.14824. Epub 2018 Jun 4.

PMID:
29863286
3.

Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC.

Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T.

Eur J Intern Med. 2018 May 30. pii: S0953-6205(18)30218-8. doi: 10.1016/j.ejim.2018.05.024. [Epub ahead of print]

PMID:
29859798
4.

Molecular endoscopic imaging in cancer.

Ahmed S, Strand S, Weinmann-Menke J, Urbansky L, Galle PR, Neumann H.

Dig Endosc. 2018 May 30. doi: 10.1111/den.13199. [Epub ahead of print] Review.

PMID:
29846982
5.

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.

Cancer Treat Rev. 2018 May 26;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. [Epub ahead of print] Review.

6.

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.

Mähringer-Kunz A, Weinmann A, Schmidtmann I, Koch S, Schotten S, Pinto Dos Santos D, Pitton MB, Dueber C, Galle PR, Kloeckner R.

BMC Cancer. 2018 Apr 27;18(1):489. doi: 10.1186/s12885-018-4407-5.

7.

The immune contexture of hepatocellular carcinoma predicts clinical outcome.

Foerster F, Hess M, Gerhold-Ay A, Marquardt JU, Becker D, Galle PR, Schuppan D, Binder H, Bockamp E.

Sci Rep. 2018 Mar 29;8(1):5351. doi: 10.1038/s41598-018-21937-2.

8.

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.

Nagel M, Schulz J, Maderer A, Goepfert K, Gehrke N, Thomaidis T, Thuss-Patience PC, Al-Batran SE, Hegewisch-Becker S, Grimminger P, Galle PR, Möhler M, Schattenberg JM.

Tumour Biol. 2018 Mar;40(3):1010428318764007. doi: 10.1177/1010428318764007.

PMID:
29534639
9.

Hepatocellular carcinoma: one world, one cancer-different guidelines?

Foerster F, Galle PR.

Hepatobiliary Surg Nutr. 2018 Feb;7(1):41-43. doi: 10.21037/hbsn.2018.01.05. No abstract available.

10.

The role of molecular enrichment on future therapies in hepatocellular carcinoma.

Nault JC, Galle PR, Marquardt JU.

J Hepatol. 2018 Jul;69(1):237-247. doi: 10.1016/j.jhep.2018.02.016. Epub 2018 Mar 2. Review.

PMID:
29505843
11.

Patient prioritisation in HCC treatment: All (good) things come in threes.

Wörns MA, Galle PR.

J Hepatol. 2018 Jun;68(6):1311-1312. doi: 10.1016/j.jhep.2017.11.035. Epub 2018 Mar 2. No abstract available.

PMID:
29496352
12.

The Manchester Triage System (MTS): a score for emergency management of patients with acute gastrointestinal bleeding.

Nguyen-Tat M, Cornelius C, Hoffman A, Tresch A, Krey J, Kiesslich R, Galle PR, Rey JW.

Z Gastroenterol. 2018 Feb 9. doi: 10.1055/s-0043-124194. [Epub ahead of print]

PMID:
29426055
13.

Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis.

Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, Gründemann D, Schattenberg JM, Gehrke N, Wörns MA, Baumgart J, Galle PR, Zimmermann T.

Oncotarget. 2017 Dec 18;8(70):115667-115680. doi: 10.18632/oncotarget.23372. eCollection 2017 Dec 29.

14.

Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation.

Gehrke N, Hövelmeyer N, Waisman A, Straub BK, Weinmann-Menke J, Wörns MA, Galle PR, Schattenberg JM.

J Hepatol. 2018 May;68(5):986-995. doi: 10.1016/j.jhep.2018.01.008. Epub 2018 Jan 31.

PMID:
29366909
15.

Advanced endoscopic imaging for diagnosis of inflammatory bowel diseases: Present and future perspectives.

Sivanathan V, Tontini GE, Möhler M, Galle PR, Neumann H.

Dig Endosc. 2018 Jul;30(4):441-448. doi: 10.1111/den.13023. Epub 2018 Feb 19. Review.

PMID:
29360261
16.

[Evaluation of Abnormal Liver Chemistries in General Practitioner Care - The Reality of Primary Care in Germany].

Jansky M, Mattlinger C, Nguyen-Tat M, Galle PR, Lammert F, Jäger J, Wangler J.

Dtsch Med Wochenschr. 2018 Mar;143(6):e34-e41. doi: 10.1055/s-0043-122251. Epub 2018 Jan 9. German.

PMID:
29316587
17.

Hepatocellular carcinoma in 2017: Two large steps forward, one small step back.

Wörns MA, Galle PR.

Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):74-76. doi: 10.1038/nrgastro.2017.174. Epub 2018 Jan 4. No abstract available.

PMID:
29300046
18.

Pretransplant coronary artery disease is a predictor for myocardial infarction and cardiac death after liver transplantation.

Darstein F, Hoppe-Lotichius M, Vollmar J, Weyer-Elberich V, Zimmermann A, Mittler J, Otto G, Lang H, Galle PR, Zimmermann T.

Eur J Intern Med. 2018 May;51:41-45. doi: 10.1016/j.ejim.2017.12.001. Epub 2017 Dec 8.

PMID:
29229303
19.

Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.

Gehrke N, Nagel M, Straub BK, Wörns MA, Schuchmann M, Galle PR, Schattenberg JM.

Am J Physiol Gastrointest Liver Physiol. 2018 Mar 1;314(3):G319-G333. doi: 10.1152/ajpgi.00097.2017. Epub 2017 Nov 30.

PMID:
29191940
20.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.

United European Gastroenterol J. 2017 Nov;5(7):987-996. doi: 10.1177/2050640617695698. Epub 2017 Feb 26.

21.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

PMID:
29150490
22.

Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study.

Tontini GE, Mudter J, Vieth M, Günther C, Milani V, Atreya R, Rath T, Nägel A, Hatem G, Sturniolo GC, Vecchi M, Neurath MF, Galle PR, Buda A, Neumann H.

Gastrointest Endosc. 2018 Jun;87(6):1505-1514.e3. doi: 10.1016/j.gie.2017.10.033. Epub 2017 Nov 3.

PMID:
29108979
23.

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A.

Dtsch Arztebl Int. 2017 Sep 4;114(35-36):597-602. doi: 10.3238/arztebl.2017.0597.

24.

Reply to: "Response to 'the flexible therapeutic approach to the BCLC B stage': Time for scoring systems?"

Foerster F, Wörns MA, Galle PR.

J Hepatol. 2017 Sep 15. pii: S0168-8278(17)32284-5. doi: 10.1016/j.jhep.2017.09.005. [Epub ahead of print] No abstract available.

PMID:
28919472
25.

Reply to: "Performance status in patients with HCC: New kid on the block".

Wörns MA, Galle PR.

J Hepatol. 2017 Dec;67(6):1353-1355. doi: 10.1016/j.jhep.2017.07.029. Epub 2017 Aug 10. No abstract available.

PMID:
28803952
26.

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.

Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T.

Drug Des Devel Ther. 2017 Jul 12;11:2131-2138. doi: 10.2147/DDDT.S139837. eCollection 2017.

27.

Epidemiology of hepatic encephalopathy in german hospitals - the EpHE study.

Labenz C, Wörns MA, Schattenberg JM, Huber Y, Galle PR, Labenz J; ALGK study group.

Z Gastroenterol. 2017 Aug;55(8):741-747. doi: 10.1055/s-0043-114671. Epub 2017 Jul 12.

PMID:
28701025
28.

Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.

Ganten TM, Stauber RE, Schott E, Malfertheiner P, Buder R, Galle PR, Göhler T, Walther M, Koschny R, Gerken G.

Clin Cancer Res. 2017 Oct 1;23(19):5720-5728. doi: 10.1158/1078-0432.CCR-16-0919. Epub 2017 Jul 11.

PMID:
28698202
29.

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.

Labenz C, Prenosil V, Koch S, Huber Y, Marquardt JU, Schattenberg JM, Galle PR, Weinmann A, Wörns MA.

Dig Dis. 2018;36(1):78-88. doi: 10.1159/000477578. Epub 2017 Jul 4.

PMID:
28675895
30.

Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu.

Huber Y, Gehrke N, Biedenbach J, Helmig S, Simon P, Straub BK, Bergheim I, Huber T, Schuppan D, Galle PR, Wörns MA, Schuchmann M, Schattenberg JM.

Cell Death Dis. 2017 Jun 22;8(6):e2893. doi: 10.1038/cddis.2017.266.

31.

Treating Hepatobiliary Cancers: The Oncology Way.

Galle PR.

Dig Dis. 2017;35(4):384-386. doi: 10.1159/000456591. Epub 2017 May 3. Review.

PMID:
28468016
32.

Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis.

Reißig S, Tang Y, Nikolaev A, Gerlach K, Wolf C, Davari K, Gallus C, Masri J, Mufazalov IA, Neurath MF, Wunderlich FT, Schattenberg JM, Galle PR, Weigmann B, Waisman A, Glasmacher E, Hövelmeyer N.

Nat Commun. 2017 Apr 28;8:15069. doi: 10.1038/ncomms15069.

33.

Immune oncology in hepatocellular carcinoma-hype and hope.

Wörns MA, Galle PR.

Lancet. 2017 Jun 24;389(10088):2448-2449. doi: 10.1016/S0140-6736(17)31044-9. Epub 2017 Apr 20. No abstract available.

PMID:
28434649
34.

Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.

Castven D, Fischer M, Becker D, Heinrich S, Andersen JB, Strand D, Sprinzl MF, Strand S, Czauderna C, Heilmann-Heimbach S, Roessler S, Weinmann A, Wörns MA, Thorgeirsson SS, Galle PR, Matter MS, Lang H, Marquardt JU.

Oncotarget. 2017 Jul 25;8(30):48688-48700. doi: 10.18632/oncotarget.16231.

35.

[Hepatocellular carcinoma].

Czauderna C, Marquardt JU, Galle PR, Wörns MA.

Internist (Berl). 2017 May;58(5):469-479. doi: 10.1007/s00108-017-0226-z. Review. German.

PMID:
28386626
36.

[Hepatic manifestation of a macrophage activation syndrome (MAS)].

Nagel M, Schwarting A, Straub BK, Galle PR, Zimmermann T.

Z Gastroenterol. 2017 May;55(5):473-478. doi: 10.1055/s-0043-106445. Epub 2017 Apr 4. German.

PMID:
28376538
37.

The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.

Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L.

J Hepatol. 2017 Jul;67(1):173-183. doi: 10.1016/j.jhep.2017.03.007. Epub 2017 Mar 18. Review.

PMID:
28323121
38.

Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.

Mähringer-Kunz A, Kloeckner R, Pitton MB, Düber C, Schmidtmann I, Galle PR, Koch S, Weinmann A.

Cardiovasc Intervent Radiol. 2017 Jul;40(7):1017-1025. doi: 10.1007/s00270-017-1606-4. Epub 2017 Feb 14.

PMID:
28197830
39.

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski CC, Staib F, Göhler T, Hebart H, Heike M, Neise M, Rudi J, Geer T, Dingeldein G, Lang C, Ehscheidt P, Flohr T, Josten KM, Karthaus M, Schmittel A, Wierecky J, Boller E, Indorf M, Wörns MA, Galle PR, Moehler M.

J Cancer Res Clin Oncol. 2017 Jun;143(6):1023-1034. doi: 10.1007/s00432-017-2344-3. Epub 2017 Feb 14.

PMID:
28197787
40.

Efficacy of image enhanced endoscopy for colorectal polyps: Are we ready for prime time?

Neumann H, Galle PR.

Saudi J Gastroenterol. 2017 Jan-Feb;23(1):1-2. doi: 10.4103/1319-3767.199120. No abstract available.

41.

Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.

Steinmetz C, Kashyap A, Zhivkova N, Alizor H, Ernst I, Gottfried-Brand D, Janssen H, Teufel A, Schulze-Bergkamen H, Lotz J, Kuball J, Theobald M, Heise M, Lang H, Galle PR, Strand D, Strand S.

Hepatology. 2017 Jun;65(6):2074-2089. doi: 10.1002/hep.29072. Epub 2017 Apr 28.

PMID:
28108987
42.

Current progress in immunotherapy of hepatocellular carcinoma.

Sprinzl MF, Galle PR.

J Hepatol. 2017 Mar;66(3):482-484. doi: 10.1016/j.jhep.2016.12.009. Epub 2016 Dec 21. No abstract available.

PMID:
28011330
43.

Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants.

Zimmermann A, Popp RA, Al-Khzouz C, Bucerzan S, Naşcu I, Leucuta D, Galle PR, Grigorescu-Sido P.

J Gastrointestin Liver Dis. 2016 Dec;25(4):447-455. doi: 10.15403/jgld.2014.1121.254.zim.

44.

Past, present and future of immunology in Mainz.

Waisman A, Hövelmeyer N, Diefenbach A, Schuppan D, Reddehase MJ, Kleinert H, Kaina B, Grabbe S, Galle PR, Theobald M, Zipp F, Sahin U, Türeci Ö, Kreiter S, Langguth P, Decker H, van Zandbergen G, Schild H.

Cell Immunol. 2016 Oct;308:1-6. doi: 10.1016/j.cellimm.2016.09.001. No abstract available.

PMID:
27719802
45.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR.

BMC Cancer. 2016 Aug 31;16:699. doi: 10.1186/s12885-016-2736-9.

46.

Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.

Kloeckner R, Pitton MB, Dueber C, Schmidtmann I, Galle PR, Koch S, Wörns MA, Weinmann A.

J Vasc Interv Radiol. 2017 Jan;28(1):94-102. doi: 10.1016/j.jvir.2016.06.012. Epub 2016 Aug 23.

PMID:
27562621
47.

Professor Dr. med. Bertram Wiedenmann - Vorstellung des Kongresspräsidenten der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten.

Galle PR.

Z Gastroenterol. 2016 Aug;54(8):731-2. doi: 10.1055/s-0042-110120. Epub 2016 Aug 16. German. No abstract available.

PMID:
27529523
48.

Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation.

Gehrke N, Wörns MA, Mann A, Huber Y, Hoevelmeyer N, Longerich T, Waisman A, Galle PR, Schattenberg JM.

Oncotarget. 2016 Jul 28;8(34):56095-56109. doi: 10.18632/oncotarget.10893. eCollection 2017 Aug 22.

49.

[Expert recommendations: Hepatitis C and transplantation].

Zimmermann T, Beckebaum S, Berg C, Berg T, Braun F, Eurich D, Herzer K, Neumann U, Rupp C, Sterneck M, Strassburg C, Welker MW, Zachoval R, Gotthardt DN, Weigand K, Schmidt H, Wedemeyer H, Galle PR, Zeuzem S, Sarrazin C.

Z Gastroenterol. 2016 Jul;54(7):665-84. doi: 10.1055/s-0042-107360. Epub 2016 Jul 18. German.

PMID:
27429106
50.

Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis.

Marquardt JU, Nguyen-Tat M, Galle PR, Wörns MA.

Visc Med. 2016 Apr;32(2):110-5. doi: 10.1159/000445407. Epub 2016 Apr 8. Review.

Supplemental Content

Support Center